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resumo 
 
 
Este relatório descreve a minha experiência de 9 meses enquanto estagiária 
nos Laboratórios Pfizer, Lda.,uma das indústrias farmacêutica mais 
especializada em pesquisa biomédica.   
 
Este estágio decorreu em dois formatos: formação multidisciplinar e 
monodisciplinar.  
 
A formação multidisciplinar teve como objectivo obter uma perspectiva mais 
alargada das diferentes unidades de uma indústria farmacêutica, envolvendo 
deste modo a participação em diferentes unidades desta empresa.  
 
A formação monodisciplinar concentrou-se na área de monitorização de 
ensaios clínicos, decorrendo na unidade de ensaios clínicos – Country Clinical 
Operations – com o objectivo de adquirir experiência e competências na 
condução de ensaios clínicos.  
 
O estágio multidisciplinar permitiu-me adquirir competências em diferentes 
unidades da companhia e perceber qual a sua função dentro da companhia. 
 
O estágio monodisciplinar permitiu-me compreender com maior profundidade o 
papel do monitor na condução de ensaios clínicos e o quão importante é para 
garantir a segurança, direitos e bem-estar dos participantes nos ensaios 
clínicos e garantir a integridade dos dados recolhidos. Permitiu me também 
contactar com locais de ensaio e perceber quais os desafios que temos de 
ultrapassar para voltarmos a ser um país de interesse para a condução de 
ensaios clínicos.  
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abstract 
 
This report describes my 9-month experience as an intern at Laboratórios 
Pfizer,Lda., one of the most specialized companies of biomedical research in 
the world. 
 
This internship took place in two formats: multidisciplinary and 
monodosciplinary training. 
 
Multidisciplinary training had the objective of obtaining a broad perspective of 
the different units of the company involving the participation in these different 
units. 
 
The Monodisciplinary training carried out in the Clinical Country Operations unit 
was focused in monitoring clinical trials. The objective was to obtain experience 
and skills in the conduction of clinical trials.  
 
Multidisciplinary internship allowed me acquire skills in each unit where I spent 
time and realize what are the functions of each unit in the company. 
 
Monodisciplinary internship allowed me to deeply understand the monitor’s 
responsibilities in conducting clinical trials, and how important is to ensure the 
rights, safety and welfare of subjects participating in clinical trials and assure 
the quality, reliability and integrity of data collected. It also allowed me to 
contact with study sites and understand what are the challenges that we need 
to overcome and become again an eligible country to conduct clinical trials. 
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Introduction  
 
From September 2010 through May 2011, I developed my internship within the scope of the Master’s degree 
in Pharmaceutical Biomedicine, which took place at Laboratórios Pfizer, Lda., a leading pharmaceutical 
company.  
I established the following main objectives to be achieved during the internship:   
 To gather basic knowledge in various areas, to be involved with activities from the different units, in 
order to understand the multidisciplinary framework of this company; 
 To understand in depth the conduction of clinical trials, working mostly within the Country Clinical 
Operations (CCO); 
 Acquire skills and experience in the conduction of clinical trials;  
 Establish networking with peers, hierarchical levels, institutions, researchers and other health 
professionals; 
 Personal and professional development.  
 
The internship was planned according to the information presented in Table 1. In January I decided the area 
where I would like to specialize, I chose Country Clinical Operations. 
Table 1 – Plan of internship 
Unit Period 
Country Clinical Operations September 1st - 10th 
Regulatory Affairs September 13th - 24th 
Drug Safety  September 27th -  October 8th 
Quality of Procedures October 11th - 22nd 
Quality of Products October 25th - November 5th 
Medical Information  November 8th - 19th 
Market Access November 22nd - December 3rd 
Medical Affairs December 6th - 31st 
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This internship report describes my working experience during the last 9 months, since September 2010 to 
May 2011, describing Pfizer and defining its role inside the clinical research environment, as well as, 
reporting all activities performed and lessons learned from such activities.  
For this purpose, this document is divided in 4 chapters, defined as follows:  
 Overview of the host company and clinical trials: this chapter describes Pfizer, defining where it fits 
in the clinical research framework, its purpose, organization and work developed. The state of the 
art of clinical trials is also described in this chapter; 
 Multidisciplinary internship: this chapter reports the activities developed in all medical related units 
of Laboratórios Pfizer, Lda, to understand the objectives and comprehend the type of work 
performed in each of these units, as well as how they fit in the company framework; 
 Monodisciplinary internship within the Country Clinical Operations  unit: this chapter describes the 
role of a monitor in the conduct of clinical trials  and the activities in which I have participated; 
 Discussion: this chapter gives an overview of my internship experience, discussing what I learned 
during this period and the acquired competences. 
 Conclusions: in this chapter I present the conclusions about my internship. 
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1. Overview of the host company and clinical trials 
 
This chapter describes the host company, its purpose, activities and its structure and an overview of clinical 
trials. 
 
1.1. Overview of the host company  
 
My internship took place at Laboratórios Pfizer, Lda., in Lisbon. Pfizer is one of the major and most 
specialized companies of biomedical research in the World, resulting from the acquisition of others 
pharmaceutical companies that have a huge worldwide growth. The objective of Pfizer is to make available 
safe, effective and affordable drugs and related health care services to the people who need them(1). 
Pfizer was funded by the cousins Charles Pfizer and Charles Erhart in 1849, and has been in Portugal for 
more than 50 years(2). This pharmaceutical company provides a huge portfolio of products and drugs in 
support wellness and prevention, as well as for treatment of diseases across a broad range of therapeutic 
areas. In the research and development area, Pfizer has an industry-leading pipeline of promising new 
products in a variety of therapeutic areas, of which I highlight Alzheimer's disease and cancer (1). Another 
objective of Pfizer is to ensure through partnerships with several organizations, that people everywhere have 
access to treatments and quality health care (1).  
Pfizer is present in 180 countries, with its headquarters in New York, and has research centers in United 
States of America (USA), Europe and Japan, as well as, some pilot centers around the World, and factories in 
33 countries (1).  
 
1.1.1. Pfizer History 
 
Pfizer was founded in 1849. From the start, this pharmaceutical company has remained dedicated to 
discovering and developing new and better ways to prevent and, to treat disease and improve the health and 
quality of life for people around the world. Since 1849, Pfizer grew and expanded to the whole World, 
acquired other companies and products, increased the investment in drug development and became more 
social responsible. At this level, worthwhile mentioning the growth of patient assistance programs, to better 
respond to the World’s diverse health needs. Along the years, the structure and managerial process of the 
company suffered several changes, turning in what can be seen today. The Table 2 describes in summary 
some of Pfizer’s milestones.  
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Table 2 – Brief timeline about Pfizer’s history 
1
8
4
9
 –
 1
9
5
0
 
Cousins Charles Pfizer and Charles Erhart open Charles Pfizer & Company.  
First product is a palatable form of santonin.  
Launch of the first domestic production of tartaric acid and cream of tartar, products vital to the 
food and chemical industries. 
Pfizer marks its 50th anniversary. Its portfolio includes a wide array of industrial and 
pharmacological products, anchored by citric acid, camphor, cream of tartar, borax, and iodine.  
Alexander Fleming discovers the antibiotic properties of the penicillin mould, an event destined to 
make medical history and to change the course of Pfizer’s future.  
Pfizer starts large-scale production of penicillin. 
Pfizer becomes the world's leading producer of vitamin C. 
Pfizer starts the production of vitamin B-2, or riboflavin, and eventually develops a vitamin mix 
that includes riboflavin, thiamin, niacin, and iron.  
Terramycin® (oxytetracycline) - is the result of the Company's first discovery program. 
1
9
5
2
 –
 1
9
8
9
 
Pfizer establishes an agricultural division dedicated to offering cutting-edge solutions to animal 
health problems. 
Pfizer introduces: Vibramycin® (doxycycline hyclate), Minipress® (prazosin HCI), Feldene® 
(piroxicam), Glucotrol® (glipizide), Unasyn® (ampicillin sulbactam), Procardia® XL (nifedipine). 
Pfizer acquires Mack Illertissen, a prosperous manufacturer of pharmaceutical, chemical, and 
consumer products. 
Pfizer also leads the ongoing worldwide battle for intellectual property protection to encourage and 
safeguard innovation. 
1
9
9
0
 –
 1
9
9
9
 
Pfizer launches: Diflucan® (fluconazole), Zoloft® (sertraline hydrochloride), Norvasc® (amlodipine 
besylate), and Zithromax® (azithromycin), Cardura® and Viagra®. 
The Animal Health Division purchases SmithKline Beecham's animal health business. 
Fortune® magazine names Pfizer the world's most admired pharmaceutical company. Pfizer 
continues its reign as most admired in 1998. 
Pfizer invests more than $3.3 billion in research and development. 
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2
0
0
1
 -
 2
0
1
0
 
Pfizer launches Zeldox® (ziprasidone hydrochloride), Relpax® (eletriptan HBr) Caduet® 
(amlodipine besylate and atorvastatin calcium), Lyrica® (pregabalin), Ecalta™ (anidulafungin), 
Champix™ (varenicline), Sutent® (sunitinib malate), Celsentri™ (maraviroc)  and Toviaz 
(fesoterodine), Vfend® (voriconazole). 
On 2003 Pfizer Inc and Pharmacia Corporation combine operations. 
Pfizer Inc. is selected by Dow Jones and Co. to be included in the Dow Jones Industrial Average, 
which is the best-known stock market barometer in the world. 
Pfizer announces the launch of Mobilize Against Malaria. 
Customer-focused business units allow Pfizer to better anticipate and respond to customers' and 
patients' needs, and to respond to changes in the marketplace. 
Pfizer launches a new Medicine Safety Website to help healthcare professionals and patients make 
better informed decisions about treatment options. 
Pfizer launches its Global Regenerative Medicine Unit. 
Pfizer acquires Wyeth, creating a company with a broad range of products and therapies. 
Pfizer announces a diversified research and development (R&D) platform named – Pfizer 
Worldwide Research and Development.  
Pfizer acquires King Pharmaceuticals Inc. 
Source: Pfizer Website (1) 
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1.1.2. Pfizer Leadership and Structure 
 
Pfizer's Executive Leadership Team is composed by the leaders responsible for financial, strategic and 
operational decisions for the company (1).  
At the level of research and development two distinct research organizations were created to maximize new 
opportunities in biomedical research and bring drugs to patients more quickly. The PharmaTherapeutics 
Research & Development Group, which focuses on the discovery of small molecules and related modalities; 
and The Bio Therapeutics Research & Development Group, which focuses on large-molecules research, 
including vaccines (1). Pfizer has also developed an enhanced commercial operating structure through the 
creation of health care businesses – Primary Care, Specialty Care, Oncology, Emerging Markets, Established 
Products, Consumer Healthcare, Nutrition, Animal Health and Capsugel. This structure, allows Pfizer to 
have a strategic vision of the market and to quickly take advantage of opportunities to advance its business by 
increasing support for successful development and delivery of new drugs, establishing partnerships with key 
stakeholders, entering into co-promotion and licensing agreements with other pharmaceutical industries, 
investing in new technologies and acquiring new products and services from outside the company (1). 
In Portugal, there is the same health care business organized on the following structure: Worldwide 
Biopharmaceutical Businesses, Diversified Businesses and Supporting Functions. In the Worldwide 
Biopharmaceutical Businesses, Portugal has four business units – Primary Care, Oncology, Established 
Products, Specialty Care, three business units in Diversified Business – Consumer, Nutrition and Animal 
Health, and several units in Supporting Functions. Supporting functions are transversal to all business units, 
and they are: Access & Public Affairs, Business Technology, Procurement, Human Resources, Country 
Clinical Operations, Legal, Safety, Medical Information, Distribution, Finance and Manufacturing. 
 
1.2. Overview of clinical trials 
 
The first clinical trials were not exactly randomized, double-blinded, placebo-controlled clinical trial. But the 
modest experiments may have been one of the first times in human history that a medical test, although 
rudimentary, guided a decision about public health (3). With the time, scientific progression and ethical 
concerns, the clinical trials became what they are in our days – with a control group, and with ways to 
eliminate the bias, such as blinding and randomization. The scientific progression was accompanied with a 
regulatory evolution. The Nuremberg Code (1947) was the only guidance document specifying standards for 
the review and conduct of human research during years. In 1960, a tragedy happened with a drug called 
thalidomide. This tragedy was the trigger for pharmaceutical companies and regulatory authorities of 
different countries to work in legislation that would regulate the evaluation of drugs before they were allowed 
on the market(4). In 1964, the Declaration of Helsinki was adopted by the World Medical Association in 
response to the findings of Nuremberg trials. Declaration sets out comprehensive ethical standards for the 
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conduct of human research and had a significant impact influencing national laws, regulations and guidelines. 
These laws, guidelines and regulations were implemented to evaluate the safety, quality and efficacy of new 
medical products in worldwide, in the sixties and seventies (4). In this period the pharmaceutical companies 
experienced a huge growth, becoming more international and seeking new markets. With different legislation 
within each country, but with the same purpose industry faced a problem: the need to do in duplicate the 
same work (4). Other problems like the over rising costs of health care, increased costs of R&D and the need 
to have safe and efficacious new treatments rapidly available created the need to harmonize legislation (4). 
This way, in 1990 the International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) was created and developed several documents, like 
quality, safety, efficacy and multidisciplinary guidelines with the aim to give answers to the problems that the 
industry was facing. Among, these guidelines developed one holds special interest for the clinical trials 
monitoring: ICH - Good Clinical Practices (GCP) (4). As stated in that guideline, GCP “is an international 
ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve 
the participation of human subjects. Compliance with that standard provides public assurance that the rights, 
safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the 
Declaration of Helsinki, and that the clinical trial data are credible” (5). 
Today, new drugs need to prove to be safe and effective before being authorized to market. It is through 
clinical trials that those parameters are evaluated. All clinical trials need to have scientific purpose – a 
rationale – and should be conducted according to scientific principles and ethical issues, in order to achieve 
the clinical trial objectives (6). 
 
1.2.1. Clinical trials classification 
 
Clinical trial is defined as stated in ICH GCP as “Any investigation in human subjects intended to discover or 
verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s), 
and/or to identify any adverse reactions to an investigational product(s), and/or to study absorption, 
distribution, metabolism, and excretion of an investigational product(s) with the object of ascertaining its 
safety and/or efficacy.” (5).  
The essence of rational drug development is to ask important questions and answer them with appropriate 
studies. The primary objectives of any study should be clear and explicitly stated. 
Clinical studies can be classified according to when the study occurs during clinical development and four 
phases are considered: 
Phase I: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its 
tolerability, safety, determine a safe dosage range, and identify side effects. This phase is carried out in 
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healthy people; however in certain diseases, like cancer, this phase is carried out in people with the disease 
being studied (7).  
Phase II: In this phase the drug or treatment is given to a larger group of people (with the study disease) with 
the objective to explore therapeutic efficacy in patients and short-term side effects and identify common risks 
for a specific population and diseases (7).  
Phase III: This phase is carried out in large group of people. The primary objective is to confirm or 
demonstrate the therapeutic benefit of study drug (7). In addition, to the confirmation of efficacy, this phase 
is useful to monitor side effects, compare the drug with standard treatments, and collect more information 
that will allow its safe use (7).  
Phase IV: These studies are carried out after the marketing authorization of the drug or treatment, and the 
principal objective is the collection of efficacy and safety information associated with long term use of the 
intervention. They are not needed to obtain the approval from authorities. However, they are important for 
optimizing the use of drug or treatment (7). 
Clinical drug development is often associated to four temporal phases. However, a classification per 
objectives is preferable, once one type of trial may occur in several phases and emerging data will frequently 
prompt a modification of the development strategy (7). For example, human pharmacology studies can occur 
during all development phases of a clinical trial, as it is presented in the  
Figure 1. This figure shows the correlation between development phases and type of studies. (7). As 
presented in Guideline E8 – General Considerations For Clinical Trials, clinical trials can be classified 
according to study objective in: Human Pharmacology, Therapeutic Exploratory, Therapeutic Confirmatory 
and Therapeutic Use (7). 
 
 
 
Figure 1 – Correlation between development phases and types of study. Reprinted from ICH E8 (7).The 
gray circles show the types of study most usually conducted in a certain phase of development, the open 
circles show certain types of study that may be conducted in that phase of development but are less usual. 
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1.2.2. Clinical trials regulation  
 
A clinical trial is a highly regulated activity due to its sensitivity relatively to ethical and regulatory issues. 
As stated above, ICH GCP is an international standard for the conduct and reporting of clinical trials. 
However, countries have specific regulations that govern the conduct of clinical trials and these must also be 
applied. In addition to ICH GCP and regulations of the country in which the trial is being conducted, trials 
may also be subject to the US Code Federal Regulations (CFR) and/or European Union (EU) Clinical Trials 
Directive, depending on where the trial is being conducted and where the data will be submitted. For 
example, trials in Europe that will form part of an investigational new drug application will need to be 
conducted in accordance with US CFR. In most cases, the additional regulations simply provide further detail 
that is found in ICH GCP. However it is important be compliant with all regulation. 
In the USA it is the Code of Federal Regulations that regulates clinical trials, specially the title 21 (21 CFR) 
that have the rules generated by the Food and Drug Administration. 21 CFR also regulates trials that are 
conducted outside of USA as part of an investigational new drug (8).  
In Europe the clinical trial directive – 2001/20/EC – provide a legal framework for the application of GCP to 
all trials conducted in member states of the EU. This directive was transposed into national law in each 
member state of the EU (9). In 2005, another directive enter in force, 2005/28/EC, establishing principles and 
detailed guidelines for good clinical practice as regards investigational medicinal products for human use 
(10). 
In Portugal, the following rules must be followed: 
European Commission Directives:  
 2001/20/EC  
 2005/28/EC  
National Law:  
 Law no 46/2004: transposition of Directive 2001/20/CE (11);  
 Decree-Law no 102/2007: transposition of Directive 2005/28/CE (12);  
 Law no 67/98: protection of personal data (13).  
Other essential Documents:  
 Declaration of Helsinki (2008 version): definition of ethical principles for medical research 
involving human subjects (14).   
To conduct clinical trials in Portugal they need to be previously approved or obtain a favorable opinion by: 
 Commission of Ethics for Clinical Research (CEIC) (11);  
 National Authority of Medicines and Health Products (INFARMED) (11); 
 National Committee for Data Protection (CNPD) (15).  
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1.2.3. Monitor role 
 
The monitor is responsible for ensuring that the trial “is conducted, recorded and reported in accordance with 
the study protocol, Standard Operating Procedures (SOPs) and all the applicable ethical and regulatory 
requirements defined above”, as stated in ICH-GCP (5).  
This visits carried out by the monitor at the study sites have the purpose, as stated in ICH GCP (5), verify: 
 The rights and well-being of human subjects are protected; 
 The reported trial data are accurate, complete, and verifiable from source documents;  
 The conduct of the trial is in compliance with the currently approved protocol/amendment(s), with 
GCP, and with the applicable regulatory requirement(s). 
 
It is supposed that the monitor(s) act in accordance with the sponsor requirements to ensure that the trial is 
conducted and documented properly, by carrying out the following activities when relevant and necessary to 
the trial and the trial site (5): 
 Be the main line of communication between the sponsor and the investigator; 
 Verify if the investigator has adequate qualifications and resources (facilities and human resources) 
and remain adequate throughout the trial period; 
 Verify, for the investigational drug(s): 
o The conditions of local (locked cabinet, temperature...), the storage times, if the supplies 
are enough throughout the trial; 
o If only eligible subjects are receiving investigational drug and in the corrects doses; 
o If staff know how to  manage the investigational drug - use, handle, store, and return; 
o If there is a proof of the following activities and if they were controlled: reception, use, and 
return of the investigational drug; 
o If unused investigational drugs are in compliance with applicable legislation and sponsor 
requirements; 
 Verify if the investigator is in compliance with the approved protocol and all approved 
amendment(s), if any; 
 Verify if all written informed consents were obtained from the subjects before any trial procedure; 
 Ensure that all essential documents and trial supplies needed to conduct the trial were received for 
the investigator, and are in compliance with the applicable regulatory requirement(s); 
 Ensure that the investigator and the investigator's trial staff are adequately informed about the trial 
and trained; 
 Verify if all investigator’s trial staff are performing the delegated trial functions, and if they are 
training or knowledge to have some duties; 
 Verify the eligibility of enrolled subjects; 
 Report the rate of subjects recruited even the screening failure must be reported; 
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 Ensure the source data verification, if the source documents and other trial records are accurate, 
complete, kept up-to-date and maintained; 
 Verify if documents provided by the investigator, like reports and submissions, are complete, 
accurate, legible, dated, identify the trial and if they are provided in the due time, according to 
applicable legislation and sponsor requirements; 
 Verify the data entered in CRF with source documents and other trial-related records in order to 
ensure the quality of data collected:  
o All data required by the protocol are reported accurately on the CRFs and in accordance 
with the source documents; 
o All therapy and its modifications are well documented for each subject. 
o Past history, adverse events and concomitant medications are reported as required by 
protocol on the CRFs; 
o Any visit or protocol procedure not performed is clearly reported on CRF, and when 
applicable documented the protocol deviation; 
 Verify if there is a report and explanation of all withdrawals and dropouts of enrolled subjects from 
the trial on the CRFs; 
 Verify if there is any CRF entry error, omission, or illegibility is found, the monitor must inform the 
investigator to correct adequately. Corrections made need to be dated, explained and initialized by 
trial staff with this duty delegated;   
 Verify if all adverse events, specially serious adverse events are reported in the due time periods 
required by GCP, the protocol, the ethics committee, the sponsor, and the applicable regulatory 
requirement(s); 
 Verify if the investigator is maintaining the essential documents; 
 Ensure that all deviations from the protocol, SOPs, GCP, and the applicable regulatory requirements 
are communicated to the investigator and appropriate action designed is implemented to prevent 
recurrence of the detected deviations. 
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1.3. State of the art of clinical trials  
 
The whole world is facing an economic crisis. The pharmaceutical industry is not an exception and is has 
also been affected. The development of successful novel drugs is decreasing in spite of the continuous rising 
investment in pharmaceutical research and development (16). The year of 2004 represented a 20-year 
decrease in introductions of new chemical entities Worldwide (17). However, the costs associated per 
successful new chemical entity  have risen to an estimated $800 million or more (16). A high rate of clinical 
failure, estimated to be of 70% – 90% of candidates, is the principal responsible for this costs (18). About 
50% of compounds tested in phase 3 trials are a clinical failure, which represents a concern of a high 
investment that will not be returned (19).  
An investment in more innovative approaches and in small markets (rare diseases) may be discouraged by the 
high cost associated of successful drug development. Additionally; the industries have a period of exclusivity 
before the launch of generics that cannot be enough to obtain the return. So, during this period some 
companies need to use “aggressive marketing techniques” (19). 
Nowadays, the pharmaceutical companies are experiencing difficulties in maintaining the innovation of other 
times. At the same time, the societal demands have been growing about the certainty of outcomes of drug 
therapy. This trend raises significant concerns, since there are several conditions that have not a therapeutic 
answer or it is unsatisfactory (16). Trends in clinical trials globally will be highly affected in the coming 
years, as we can see in the Table 3.  
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Table 3 – Change drivers in clinical trials 
Change drivers 
Pressure on Pharma R&D 
spend  
 R&D expediture is directly linked to the budget allocated to clinical 
trials. 
 R&D costs exhibited continuous, long-term growth. However, as from 
2004 R&D productivity declined. 
Increase disease prevalence  
 Epidemiologic studies may indicate therapeutic areas where demand for 
drugs, and thus clinical trials, will increase. 
Blockbuster patent expiry 
Will reduce clinical trials 
Spending 
 Several patents will expire; pharmaceutical companies will be exposed 
to revenue declines as a result of patent expiring. This can have an 
impact on the launch of new products. 
Patient empowerment will 
increase 
 Patients and patient groups will have more participation and influence 
on recruiting, protocol and information sharing through a networked 
community. However the ethical concerns and pressures will continue 
to increase. 
Treatment personalization 
&Pay for performance 
 The practice of personalized medicine will require specific clinical trial 
design. 
 Life licensing: cumulative testing and release of the drug throughout its 
lifecycle. 
 Outcome-focused clinical trial designs. 
Source: PwC, 2011 (20)
 
With the purpose to fight this crisis a set of policies have been implemented through initiatives such as 
Innovative Medicines Initiative (IMI) in Europe and Critical Path Initiative (CPI) in the USA that has the 
objective to build a more collaborative system for pharmaceutical R&D and to accelerate the development of 
more effective and safe drugs for patients (16, 21). 
Randomized clinical trials have been the mainstream of pharmaceutical product development for decades, but 
they need to be designed and carried out in a different way in the future, to sustain the drug development. 
Interactive technologies, interaction between companies and academies, development and validation of 
biomarkers, adaptive designs and new ways to recruit and monitor patients need to be developed and 
implemented (22). Clinical research needs a revolution to be able to return to the old times and develop 
successful drugs.  
One issue that arose in the last years is the decrease of clinical trials conducted in the EU and USA and its 
increase in other countries, like Asian countries, and European Eastern countries. Emerging markets are 
characterized for having access to large patient populations to run the trials. This is one reason why these 
countries are attracting a growing number of large-scale clinical trials. Another advantage of these countries 
is the lower costs associated of running clinical trials, comparing to EU and USA, and this is the explanation 
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of the drop in clinical research in EU and USA (20). Existence of improved guidelines and simplified 
procedures from authorities in emerging markets are other reason. When the pharmaceutical companies 
facing good established networks that allow the quick approval of clinical trial versus a complex and too long 
approval process; the preference goes to those that offer better conditions and where companies know that 
will obtain the return of investment (23).   
Another point that has gained presence in clinical research over the last years is the outsourcing of clinical 
development as a whole or in parts. This has become an important strategic issue for pharmaceuticals that 
have in the Clinical Research Organization (CRO) the opportunity to save costs, since CRO presents 
competitive prices, and obtain services with high quality. The services outsourced can include the entire drug 
development process, or only few phases of the program. With this strategy the industries reduce the time to 
launch the product in the market, and expenditure on new drug development (24). Outsourcing strategies can 
vary from the requirements of the sponsor and CRO. However in the last years  outsourcing of drug 
development has gained more acceptance (24). 
 
1.4. Clinical trials in Portugal 
 
The clinical trials setting in Portugal is facing some challenges, as probably many other countries. Regulatory 
demands have been increasing, there is a decrease of innovative drugs, other countries offer better conditions 
to run clinical trials and clinical trials are getting more complicated and demand more resources. With these 
facts, it is expected a decrease in the number of clinical trials performed in Portugal.  
The Portuguese regulatory authority – INFARMED has available data from the last years, Figure 2, that 
show the decline of clinical trial application (CTA) submitted since 2006 to 2010 (25). In spite of the R&D 
crisis, one possible reason for this decrease is the fact that the sponsors choose others countries to carry out 
the clinical trials. 
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Figure 2 – Number of Clinical Trial Applications done between 2006 and 2010. 
Source: INFARMED, 2011 (25) 
 
 
Figure 3 – Total Number of Clinical Trials per Phase per Year. 
Source: INFARMED, 2011 (25) 
 
As we can see in Figure 3, in Portugal, early phase trials have a small representation, while phase III 
represents the major percentage of trials performed. Phase IV have decreased in the last four years. In 
general, all phases suffered reductions since 2006 to 2010. Although the total number of clinical trials is 
decreasing, the total number of amendments is increasing, as we can see in Figure 4. 
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Figure 4 – Number of substantial amendments notified for authorization 
Source: INFARMED, 2011 (25) 
 
Portugal has a big problem: the majority of clinical trials performed in Portugal are funded by Sponsors 
(pharmaceutical companies) and there are very few from academic initiatives, as it is presented in Table 4. 
This means that most R&D developed in academic context is not always “translated” into clinical research.  
 
Table 4 – Clinical Trials funding- number of clinical trials carried out per sponsor. 
 
Source: INFARMED, 2011 (25) 
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Notifications submitted Notifications Authorised
                                     Year 
Sponsor 2006 2007 2008 2009 2010 
Pharmaceutical Company 
145 127 139 103 101 
Academic institution 8 5 
7 12 6 
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During these years there was no significant shift in the spread of clinical trials over the different therapeutic 
areas. Antineoplastic and immunomodulating, anti-infective and drugs for the nervous system represent the 
three areas where Portugal carries out more clinical trials as show Table 5.    
 
Table 5 – Number of Clinical Trials per therapeutic area between 2006 and 2010. 
Years 
Therapeutic area 2006 2007 2008 2009 2010 
Antineoplastic and immunomodulating 49 36 
43 36 41 
Anti-infective 
10 14 19 7 10 
Nervous System 20 
14 25 24 11 
Cardio Vascular  11 10 
9 12 11 
Sensory organs 13 4 
10 7 5 
Blood and blood forming organs 17 9 
12 6 4 
Endocrine System 8 7 
1 3 6 
Genito urinary 2 6 
6 5 4 
Respiratory 11 4 
3 2 5 
Alimentary tract and metabolism 4 3 
13 5 8 
Musculo-skeletal 5 3 
4 5 2 
Dermatologicals 3 2 
0 3 0 
Various 0 1 
1 0 0 
Total (nº trials submitted and authorized) 153 113 
146 115 107 
Source: INFARMED, 2011 (25) 
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2. Multidisciplinary internship  
 
In this chapter I describe the units where I spent time in multidisciplinary internship, as well as the activities 
performed in each one. 
One of the objectives of my internship was to acquire multidisciplinary knowledge and experience through 
the training in each unit. The purpose of these activities was to get a broad perspective of what happens in 
each unit, how they contribute for the Pfizer objectives and how different units interact within the company.  
The initial strategy suffered some alterations and because of the lack of human resources in CCO, I started 
working earlier in this unit.  
I participated in various activities, during my internship. Some were mandatory; others were performed only 
within the scope of this internship. I performed several activities within the following units that will be 
discussed in depth, separately:  
 Regulatory Affairs 
 Drug Safety Unit  
 Quality of Products 
 Medical Information 
 Market Access 
 Medical Affairs – Primary Care business unit 
 
All these units, except the Primary Care business unit, are Supporting Functions units transversal to all 
business units in Pfizer.  
Before executing any task within these units, the reading of applicable SOPs, legislation and sometimes some 
journal articles was essential, in order to have a minimal training and be aware of some tasks that I would 
perform. The time that I spent in each unit was managed by the head of each unit, who established a program 
of tasks and presentations that would be enough for me to be aware of all the work performed in each unit. 
Time management, good work structure and people available to demonstrate it knowledge and skills were 
essential to transmit what a unit does in a short period of time.  
 
2.1. Mandatory actions  
 
At the beginning of my internship, I had a welcome session, where I was taught about the Pfizer’s history and 
structure, as well as procedures about the functioning of the building. I also attended an internal 
pharmacovigilance training session, mandatory for all collaborators, on how to properly handle safety 
information. Aspects addressed included definition of safety information, handling of relevant safety 
information and procedures to adequately report this information to the drug safety unit.   
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2.2. Regulatory Affairs unit 
 
Regulatory Affairs carries out functions of business support, across the entire lifecycle of drugs: research and 
development, product registration, launching and marketing authorization (MA). The maintenance of MA 
involves updating the quality, safety and efficacy information in accordance with current scientific 
knowledge in order to ensure compliance between what is approved by regulatory authorities and what is 
manufactured and marketed (2).  
The activities developed in this unit had the purpose to give me an idea about what is done there. I started 
with a presentation about the unit and what are the functions and responsibilities of this unit. To be aware of 
applicable legislation the reading, prior to start any activity of Notice to Applicants Volume 2 (25) and 
Portuguese legislation – Decree-Law no 176/2006, 30 August (26) and clarification of some questions with 
different elements were crucial. The first activity developed was the simulation of the submission of CTA to 
authorities and submission of amendments. Another procedure discussed was the marketing authorization 
process. All procedures were discussed in detail – national procedure, mutual recognition procedure; 
centralized procedure and decentralized procedure. I had the opportunity to follow a centralized procedure 
during my internship in this unit. One important challenge in this kind of submission is the timelines 
established that need to be met. A related activity with the MA is the submission of alterations. Updated 
information is sent to authorities to maintain the product authorized and all information available to 
authorities updated. A package with all information is prepared to notify the authorities. I had the opportunity 
to prepare this package with the supervision of a regulatory officer. The activity most often performed was 
the revision of labels and artworks using a specialized tool. It concerns the revision of carton information 
versus the information that needs to be present and the revision of dimensions of the carton. Another activity 
often performed was the revision of a summary of product characteristics (SmPC) and package leaflet in 
accordance with the information presented in English version. I also performed a search with a regulatory 
officer with the purpose to find possible patent violations to Pfizer products through a search in the web page 
of INFARMED, of products that obtain authorization from the INFARMED during the patent period of 
Pfizer products. This way it is possible to monitor the regulatory evolution of major competitors and to 
anticipate emerging challenges. By curiosity I read the regulation applicable to nutritional products (27-29). I 
also attended also a presentation about the quality in this unit that is achieved through the following tools: 
audits, change controls, contact report and metrics. 
The partnerships, acquisition of new companies or products, co-licensing were some subjects discussed to 
show me how it is possible take benefit from the law and how this unit contributes to the growth of company.   
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2.3. Drug Safety unit 
 
This unit has a great knowledge of the safety profile of products, to properly assess their benefit-risk and 
avoid harming the health of those who use them daily. The responsibility of this unit is the management of 
adverse events and notification of any adverse event to regulatory authorities (2). 
First of all I attended a presentation about this unit and discussed its responsibilities and functions. All 
applicable SOPs for this unit were read as also the following regulatory documents: Decree Law no 
176/2006, 30 August and Law no 46/2004, 19 August. To manage the tool used to do the report of adverse 
reactions a specific training is needed. Since I cannot manage this tool, I followed all the procedure of data 
entry and peer review of data, in order to have a case validated. Doing the follow up of adverse reactions with 
the reporters is crucial to obtain more information about the adverse effect and to follow the development of 
the event and to clarify some misunderstandings. Another activity performed with collaboration of a 
colleague was the processing of adverse reactions and transform it in a line listing. I performed a weekly 
bibliographic revision in Portuguese journals. The objective of this revision is to find some adverse reaction 
related to Pfizer products in the literature that was not reported to the pharmacovigilance. I attended a 
presentation about periodic safety update report and discussion about its composition, and also a presentation 
about pharmacovigilance in clinical trials, since I had showed interest in continue my internship in the 
conduction of clinical trials. The report of all events is fundamental to continuously acquire more safety 
information about the drug, and basing on that do a benefit-risk evaluation. All the procedures to follow 
when an adverse event, a serious adverse event or a suspected unexpected serious adverse reaction occurs 
during the conduction of a clinical trial and all timelines that need to be followed were discussed.  
 
2.4. Quality of Products unit 
 
This unit is responsible for (2): 
 Ensuring the quality, safety and efficacy of drugs and products that Pfizer provides; 
 Ensuring its quickly availability for distribution to the market; 
 Ensuring monitoring throughout the period of life, while in the supply chain. 
 
The mission of this unit is to ensure the quality of drugs and products provided by Pfizer, whether for human 
or animal health, developing all necessary actions, strictly complying with all regulatory and internal 
requirements, while ensuring rapid access to people who need them. 
Like in the other units I attended a presentation about the unit and its responsibilities. Releasing of batches of 
drugs, after the previous verification of the sample and analysis certificate, is one of the tasks performed. It 
was essential to be aware of the quantities in warehouse in order to have drugs available to enter in the 
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market. If something is not available in the market and in warehouse, as soon as it turns available its release 
to the market is crucial. A very good management is needed to maintain available all drugs. 
Another activity developed in this unit is the management of quality complaints, its follow up and its 
registration in a specific system. Be aware of changes in drugs and have a broad knowledge in each drug is 
fundamental to promptly answer to all questions. 
The revision of artworks in this unit concerned information about the price, bar code and the Braille 
information were another activity performed. The tool used was the same that in regulatory affairs unit. To 
do this, I had one document with all information needed to be in carton. Organizing the drug library was 
another task performed. The drug library has one sample of each batch of all drugs that are commercialized. I 
did the registry of new entries at the drug library. 
 
2.5. Medical Information unit 
 
The medical information unit's mission is to provide excellent medical information about Pfizer's products or 
on diseases related to them, through planning, development and implementation of programs and tools 
directed both for external customers or for internal order to ensure the safe and effective use of Pfizer 
products and support the therapeutic decision (2). 
Tasks performed: 
• Overview of the structure and functioning of the European model of medical information;  
• Presentation of the medical information centre and its responsibilities; 
• Presentation of the system used to do the management of scientific questions; 
• Reading of applicable legislation applicable to medical information (e.g. copyright) (26); 
• Sources of information and research methods of scientific information; 
• How to prepare an answer to external customers – the structure to be followed and the information 
that can be given; 
• Prepare an answer after research applying the techniques learned; and review the answers prepared. 
 
2.6. Market Access 
 
This unit is responsible for planning and implementing strategies, programs and partnerships with 
government entities and key customers in the area of healthcare, including scientific and professional 
associations, pharmacies and media, as well as the planning and implementation of financing and 
reimbursement (2). 
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Tasks performed: 
 Overview of the structure and functioning of Market Access unit; 
 Overview of programs and partnerships with different stakeholders;  
 Reading of the applicable legislation (30, 31) for establishment of prices and reimbursement: 
o Decree Law no 106-A/2010, 1 October;  
o Ordinance no 1041-A/2010.   
 Reimbursement policy – discussion about the establishing of the drug price and its reimbursement, 
how the procedure is carried out to obtain a price and reimbursement, what is the applicable 
legislation, and the importance of reimbursement in our days, since the drugs are more innovative 
and consequently more expensive;   
 Preparing a request for a generic reimbursement, taking into account that the economic advantage 
for each generic drug for reimbursement purposes, after (and including) the 5th generic marketed, is 
established towards a retail price fixed at least 5% below the maximum retail price of the last 
generic whose reimbursement request was approved; 
 Overview and discussion of pharmacoeconomic studies: cost-benefit, cost-utility, cost-effectiveness 
and minimization of costs. Reading some articles and exploration the pharmacoeconomic study for 
Inspra®.  
 
2.7. Medical Affairs – Primary Care business unit 
 
The mission of medical affairs of each business unit is to provide expertise and scientific knowledge to the 
cross functional teams, and other key partners, in support of strategies (2). 
Tasks performed: 
 Overview of the structure and functioning of Primary Care business unit;  
 Presentation and definition of the positioning of medical scientific liaison and major 
responsibilities with regard to other areas / positions of the company. This role has several 
activities transversal to the whole company that starts prior to the obtaining of marketing 
authorization, prepare the medical community for the new drug, continue with its introduction 
in the market and finalize with its withdrawal. The medical science liaison is a professional with 
a bit of clinician (scientific knowledge) and salesperson (marketing knowledge) mixed in;   
 Search about some drugs of other companies – study the market – and explore the possibility of 
co-licensing;  
 Attendance of a cross functional team meeting (Inspra®) with the objective to verify the 
interaction of different elements from different units that work with the same purpose. In these 
meetings, the knowledge of each one is shared with the rest of the team, creating a good and 
creative work environment; 
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 Training in Lyrica® – this is one of Pfizer drugs. The training was given with the objective of 
having more information about this product and follow its development in different therapeutic 
areas;  
 Attendance of the “XVIII Jornadas Internacionais do Instituto Português de Reumatologia” with 
the goal to contact with key opinion leaders. 
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3. Monodisciplinary internship 
 
In this chapter I describe the CCO mission, gave some information to contextualize the activities performed 
and describe activities executed.  
Monodisciplinary internship occurred in CCO, a Supporting Function unit, the unit responsible for carried 
out clinical trials in Portugal, since 2003. The main goal of this unit is: 
“To undertake high quality clinical trials, contributing to the launch of effective and safe drugs and giving to 
our researchers’ experience with these products prior to its launch in the market.” 
Rebelo, 2010 (26) 
CCO has a team responsible for conducting clinical trials in Portugal and has an active voice contributing on 
evolution of legislation on clinical trials in Portugal. CCO is responsible for several activities, such as 
execution of feasibilities, conducting and monitoring of clinical trials.  
In the framework of this unit I carried out conduction and monitoring activities from the perspective of a 
clinical trials monitor.  
At the starting point of my internship, I needed to acknowledge the basic procedures of the company as well 
the procedures related to the monitor’s role, before enrolling in any project related activity. The training 
process of monitor at Pfizer consists of 4 phases: 
 Reading of Portuguese SOP and Guidelines described in CCO training curriculum; 
 Performing trainings in an interactive web based platform called Power2Learn; 
 Attendance in monitor workshop;  
 Performing co-monitoring visits. 
 
The training at CCO starts with the reading of company’s SOPs which have the objective to promote 
guidance to the new members and collaborators of Pfizer. All collaborators need to be trained about rules, 
procedures and codes that rule their job. These SOPs are frequently updated. This way, during the internship 
some SOPs were read more than once, when they were updated. Apart from these SOPs, I was assigned to do 
a set of trainings in an interactive web-based platform called Power2Learn. The trainings in this platform 
were diversified; there were trainings of international SOPs and programs such ELARA, electronic case 
report form (CRF) and Rightrack II, useful tools in monitoring, etc. The trainings allowed me to contact for 
the first time with a variety of documents and tools necessary to perform my future tasks. 
Training in GCP was approached in the set of web-based trainings. It was to crucial receiving training in 
GCP since these practices are fundamental for the execution of all monitoring tasks.  
A monitor workshop was done in Paris and approached all relevant issues to conduct clinical trial 
monitoring. In addition to the theoretical component, the workshop had a strong practical component, 
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allowing the exchange of views with senior professionals, presentation of solutions for common findings and 
how to avoid them, and networking establishment, since there were professionals across Europe present in 
this event. The content of workshop covered all crucial topics to monitoring. 
Monitor Workshop Content:  
 Research and development foundations; 
 Informed consent foundations;  
 Investigational product foundations; 
 Safety foundations; 
 Selecting investigators and sites work process; 
 Investigator meetings work process;  
 Performing a site initiation visit work process;  
 Clinical monitoring work process;  
 Site closure work process; 
 Audit and inspection work process. 
 
In CCO I was allocated to different projects with the objective of cooperating in various stages of 
development of a clinical trial, since its submission and initiation, to monitoring and completion. The co-
monitoring visits were done with a senior monitor. The different tasks performed are organized in the 
following phases: 
 Planning and initiation; 
 Monitoring; 
 Closeout visit; 
 Quality; 
 Others. 
 
3.1. Planning and Initiating 
 
Planning and initiating a clinical trial consists in many activities, the majority of which involve completing 
the proper documentation and obtaining the necessary approvals to conduct the clinical trial. This phase 
involves communicating and working with the authorities and investigators. Documentation is critical to the 
clinical research process and all parts involved need to be aware of its responsibilities in order to open the 
site. The initiation process should be conducted efficiently and  responsibly for the trial to start as scheduled 
since the subject enrolment cannot begin until all the initiation activities have been accomplished and 
documented (27).  
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Before discussing the activities in which I was involved in the initiation of a trial, it is important to have an 
understanding of four documents that are used in the planning and initiation of a clinical trial. They are: 
 Investigator brochure; 
 Protocol; 
 Informed consent; 
 CRF.  
 
The information in the protocol specifies how the study is to be conducted and together with the investigator 
brochure and informed consent document it provides the monitor and investigator with the information 
necessary to conduct the trial. The CRF provides the investigator with a structured place to document the data 
gathered for the individual subject during the trial. It is important that the monitor understands each of these 
documents to be comfortable to discuss them with the principal investigator.  
The activities performed at this level were regarding pre-trial visit, communication with authorities, site 
documentation requirements, investigator meeting, trial initiation visit and revision of essential document 
file.   
 
3.1.1. Pre-trial visit 
 
This visit is a key part of the investigator recruitment and selection process. However this does not indicate 
that the decision has been made by the sponsor to place a study at the investigational site.  
As a monitor, I performed one pre-trial assessment (PTA), which has the purpose of ensuring that potential 
investigators meet the appropriate scientific and ethical standards and have the ability to carry out the 
proposed study according to the protocol, including the protocol-specific site requirements and ICH GCP 
standards. The PTA process is performed to evaluate, verify and document that the investigator is qualified, 
trained and suitably experienced to conduct the study, and that the site has adequate physical resources and 
staff to conduct the study. If some resources are not available, the monitor has the responsibility to find a 
solution if the site is a potential selected site to perform the trial. One common resource is the fridge or 
locked cabinets. It is important to be careful in the site selection process since we can compromise the 
protocol compliance and recruitment if the human resources are not qualified.   
In collaboration with the investigator, I prepared the recruitment plan for the study taking in to account all 
specified protocol requirements, the hospital past history, and concurrent clinical trials, in order to obtain a 
number of possible patients eligible to enter into the study. It is essential to be realistic in this number 
because recruited patients are one of the metrics implemented in the CCO and it is preferable to appoint a 
lower number and recruit more than the opposite. It is not possible to guarantee numbers, but there are many 
ways to calculate a realistic number. Discussion with the investigator and the proof of past history are the 
essential tools to obtain it.  
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3.1.2. Authorities (regulatory authorities and ethics committee) review and approval / favorable 
opinion 
 
The submission of the key documents to the authorities is very important to obtain an approval from them. 
There are some trial documents such as protocol/amendments, informed consent, safety information, and 
others that should be reviewed by the authorities. These documents are present in the initial submission to 
authorities done through a CTA format. 
To carry out clinical trials in Portugal, the authorization of the INFARMED, CEIC and CNPD is necessary as 
well as the authorization of hospital administration boards. I carried out submissions to these authorities and 
institutions as explained in the following sections. 
 
3.1.2.1. Submission to regulatory authorities and ethics committee  
 
Submission process of a clinical trial to INFARMED and CEIC is done in parallel and through a package that 
contains: 
 Presentation letter; 
 Proof of tax payment to INFARMED;  
 CD-ROM with the CTA with all required documents organized in folders and list J; 
 Annex I filled (paper and electronic way). 
 
To obtain the validation of request for authorization to run a clinical trial by the authorities, the request 
should be in accordance with the law. The sponsor should also ensure that the request has all elements 
required by law.  
For the submission of CTA, the sponsor or the legal representative should present a requirement (presentation 
letter) to authorities with all required information, such EudraCT number, protocol number and title, and 
other relevant aspects, for example, if the trial is conducted in pediatric populations. All information sent to 
authorities should be listed in this requirement, for example, the proof of payment, the CTA, and other 
relevant documents. 
Sponsor should also send a form which identifies the clinical trial and the entity and people responsible for 
the conduction of the study. This form, called Annex I is used in first submissions and contains all data set 
required for the submission. The Annex I describes all parameters of the study, since protocol and 
investigational product to legal representatives of the clinical trial in each country. The Annex I is obtained 
through the EudraCT web page, which is a database of all clinical trials commencing in the European 
Community. It has been established in accordance with Directive 2001/20/EC, and it is in this database that 
the sponsor can modify, validate, compare and save xml/pdf files of CTA to prepare a package for 
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submission to authorities. This file is sent in two formats to authorities, electronically in a CD-ROM with the 
CTA, and one copy dated and signed in paper with the request.    
Since the submission is done electronically, the structure for the electronic submission is available in the web 
pages of authorities. This CTA presents several folders organized in different subjects in which the sponsor 
must put the applicable documents. These folders are recorded in a CD-ROM and sent with the request to 
authorities. The List J also must be sent with the request; this is a document checklist that helps to verify if 
all required documents for authorities are presented in the request. 
The following two paragraphs do not belong in this section (Planning and initiating); however, I preferred to 
mention this subject in this section, with the first communication to authorities, because the procedure is 
similar. 
The procedure to notify authorities of amendments to protocol is similar to the initial submission, however 
there are less documents involved. The notification of substantial amendments to authorities is done through 
a document entitled “Annex II”, that can be found in the web pages of authorities. It is a detailed guidance on 
the request to the competent authorities for authorization of a clinical trial amendment. Annex II highlights 
the changes in the clinical trial since the last submission, and must be signed and dated. When an amendment 
is submitted to authorities, it is also necessary a presentation letter with relevant information, pay a tax, send 
all CTA folders only with the updated documents in CD-ROM, and the updated Annex I.  
At the end of the trial, the Annex III must be sent to authorities. This document is a detailed guidance to the 
declaration of the end of the trial, describing the reason for the termination of the study. This Annex III is 
sent with one letter to authorities who introduce the notification of the end of the clinical trial.   
Using all updated forms and folders that are available in the web sites of the authorities is considered a best 
practice; this way, there is no risk of submitting an obsolete annex, form or folder. 
  
3.1.2.2. Submission to CNPD (National Data Protection Committee) 
 
This committee evaluates if the data collected during the clinical trial compromises the integrity and privacy 
of the participants. The submission is done in a form available electronically in the web page of CNPD, 
which requests information about the purpose of data collection, what data are collected, if data is transferred 
for other countries and how the data protection is done. Some documents are sent to CNPD, such as CRF, in 
order to help with the judgment. This committee always put questions regarding the collection of data about 
the ethnicity of the subjects, so it is important to pro-actively justify why this data is important in the clinical 
trial in order to avoid questions and save time. 
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3.1.2.3. Submission to Hospital Administration Board  
 
After we receive approval from all of the aforementioned authorities, it is necessary to obtain approval from 
the administration board of the hospitals. A folder with the following documents is submitted to the 
administration board for their evaluation: identification of the sponsor and investigator identification; 
regulatory authority, ethics committee and data protection national committee approvals; protocol; synopsis; 
informed consent; assurance certificate; principal investigator Curriculum Vitae; clinical agreement and 
financial agreement. 
 
3.1.3. Site documentation requirements  
 
During the site initiation, there are a number of documents that the sponsor must send to the investigator and 
that the investigator must send to the sponsor. Until the proper documentation has been completed and 
received by both parties, the investigational product cannot be shipped and subjects cannot be enrolled. I was 
actively involved in the process to get all documents from the site as well as prepare and send documents 
required.  
The following documents were sent to the investigator: 
 Sponsor-approved final version of the protocol; 
 Prototype consent form document and/or consent form guidelines; 
 Required regulatory documents (e.g. form FDA 1572); 
 Approved investigator brochure; 
 Financial disclosure information and/or forms; 
 Signed agreements (e.g. confidential and financial agreement) between appropriate involved parties; 
 Documents submitted to the ethics committee and regulatory authorities for consideration; 
 Approval from ethics committee and any other documents given approval/favorable opinion, such as 
regulatory authority; 
 Composition of ethics committee. 
The following documents were received from the investigator: 
 All required contractual agreements; 
 Sponsor-approved version of the protocol, signed and dated by the investigator; 
 Any written information to be provided to study subjects; 
 Up to date curriculum vitae for the principal investigator and any sub investigator(s); 
 Copies of applicable laboratory reference ranges; 
 Appropriate financial disclosure information. 
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Most documents are forms that were personalized according to sites’ information. However other documents 
needed to be created or translated to Portuguese. Regarding this last point, I performed the following 
activates: 
 Translation and revision of translation of informed consent and informed consent for 
phamacogenetics, and exposure in utero document; 
 Translation and revision of translation of synopsis; 
 Preparation of documents to confirm the authorization of head of unit of hospitals where the clinical 
trial will occur, in this document the head of unit ensures that its unit has qualified human resources 
and facilities to run the clinical trial; 
 Preparation of documents related with the infrastructure, research teams and equipment necessary 
for the processes of submission to the ethics committee;  
 Development of the budget of one clinical trial for Portugal: 
o It was necessary to take into account all procedures present in the protocol, how many 
times they are performed, if are locally or centrally performed, and according to Ordinance 
no.839-A/2009, 31 July and Ordinance no.1320/2010, 28 December that establishes the 
price and tax to each procedure. It is also important to take into account other possible 
costs such as initial submission, amendments, materials, and others. The objective is to 
assign a cost for each patient per clinical trial, and according to the number of patients to be 
recruited, the total cost of the trial in Portugal.  
 Preparation of clinical agreements: 
o This document states the obligations and responsibilities of the principal investigator and 
sponsor during the conduct of the trial;  
 Preparation of financial agreements with the hospitals: 
o There are two options: the hospital has a template for financial agreements and we need to 
follow this template, or they do not have one and we use a Pfizer template. In both cases, 
we need to define the cost of each patient in the clinical trial in accordance to the current 
prices described in the law (Ordinance no. 839-A/2009, 31 July and Ordinance 
no1320/2010, 28 December). Before obtain the needed signatures in the financial 
agreement a good practice is the revision of the parts involved, in order to avoid issues and 
save time.  
 Blinding plan:  
o Due to the specifications of investigational product and the protocol design, the 
development of a blinding plan is essential in order to ensure that all blind parts are really 
blind during the conduction of the study. The document provides both a generic and site-
specific overview of the procedures and documentation necessary to maintain a regulatory 
acceptable level of blinding at the institution.  
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3.1.4. Investigator meeting 
 
The investigator meeting is valuable opportunity to further enhance communication between sponsor and 
investigators. The meeting is organized by the sponsor and typically held at a central location. The meeting is 
a working session to promote consistency of practice among sites in a multi-center trial. The meeting serves 
as an opportunity to review the protocol, with emphasis on the inclusion and exclusion criteria, and the 
means used to capture trial data; identify and clarify responsibilities; review plans for recruitment of subjects 
and the difficulties to recruit; clarify all protocol procedures; review safety information regarding report of 
serious adverse event and adverse event. Provide information about the audit process is also discussed as well 
the publication issues. This is the opportunity to have the whole team involved in the clinical trial together, it 
is an occasion to establish professional relationships and supportive peer networks and reach a common 
understanding about all aspects of the study. The investigator’s meeting is an opportunity for investigators to 
suggest some amendments if the protocol does not fit the usual care of the hospital or the guidelines and 
procedures of a particular country or unit. 
I attended one investigator meeting. The goal of this meeting was to remember the investigators of them 
commitment regarding the number of subjects needed to recruit, since the recruitment rate was very low. All 
topics above mentioned were discussed, however it was very important to clarify some questions regarding 
the conduct of the study and the eligibility of subjects, share difficulties, issues, and challenges that other 
countries had and discuss and find possible solutions. It was very important because we meet all people with 
whom we usually “talk virtually” and I felt that we all share the same team spirit - working for the same 
purpose. 
 
3.1.5. Trial Initiation Visit 
 
The purpose of this visit, that I also performed, was to finalize the preparation of the trial in the form of a 
meeting. This meeting took place after receiving the regulatory authority approval. It was conducted by the 
monitor and attended by the site staff involved (27).  
During this visit the following aspects were discussed: protocol (all protocol aspects must be discussed and 
clarified), informed consent, documents like: the investigator brochure, drug and laboratory supplies, 
signature sheet, CRF, adverse events, GCP, monitoring, procedures concerning audits and inspections and 
equipment.  
Since the reporting of adverse events is a critical investigator responsibility, it was important to perform a 
more detailed discussion on important safety definitions, criteria and classifications.  
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This visit is for some trial staff the first contact with the protocol, so it is very important that all procedures 
are understood, questions are clearly answered and that after this visit the staff is able and ready to start 
patient’s recruitment.  
This visit is usually very tiring for the monitor as well as for the study team, so it is important that the 
monitor uses the best ways to capture the attention of the team. Henceforth, power point presentations and 
practical examples, such as the filling of CRF’s, should be used by the monitor. After the visit, it is essential 
to carry out the elaboration of site initiation report, where we can describe what was discussed during the 
visit.  
 
3.1.6. Essential Document File 
 
Regulatory guidelines specify that the trial must be documented. This is achieved through the archiving of 
essential documents in site master file at site and trial master file at sponsor office. The documentation 
requirements allow the trial events to be recreated and also serve as an audit trail to verify the conduct and 
results of the trial. Site master file was sent to the site prior to the beginning of the trial, and can also be 
called investigator file. It is organized by tabs and contains copies of the documents that the site had sent to 
the sponsor and the sponsor to the site. The site then maintains the file, adding documents as appropriate. All 
required essential documents required must be filed in the investigator file before trial initiation. Any missing 
documents must be obtained and filed before enrolling the subjects. The list of essential documents needed 
before the clinical phase of trial starts is specified in ICH E6 (5).  
During my internship I had the opportunity to organize these files, which gave me a continuous learning and 
training in one of the essential activities that a monitor has to perform in his day-to-day work in order to 
perform a good monitoring. A study generates a huge amount of documentation. I needed to make sure that 
they are all are correctly archived. Archiving a document on a wrong file can have unintended consequences. 
The monitor should have a good working method for the preparation, organization and updating of these 
files. 
It is very important during the conduct of the trial to verify if all forms/logs implemented are the updated 
version, and when new versions are implemented, it is essential to document the transition from the old 
forms/logs to the new ones. When something is not in the file, it is good practice to write a note to file 
explaining why this happens (note to file).  
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3.2. Monitoring 
 
Monitoring by the sponsor is a requirement of ICH GCP. Monitors are extremely helpful to the investigator 
and the site staff since monitors can provide valuable insight on the site’s performance in conducting the trial 
and they are also an excellent resource that can share their knowledge and expertise with the site staff.  
On-site monitoring visits are conducted at regular intervals after the study is initiated. Frequency of visits is 
determined by a number of factors, such as study design, length of study, complexity of study, 
recruitment/enrolment rate, sites compliance with the protocol and, the experience with clinical research. The 
monitor oversees the progress of a clinical trial and ensures that it is conducted, recorded and reported in 
accordance with the protocol, sponsor SOP, ICH GCP guidelines and applicable legislation.  
 
3.2.1. Site-monitor communication  
 
Site visits provide opportunities for the investigators to discuss trial issues with monitors. It is important to 
maintain regular contact with the site via telephone, letters, mails and/or faxes. These communications 
confirm the study progression at the site, address problems (if any), and inform the site of upcoming on-site 
monitoring visits. All essential communications must be recorded and all pertinent issues must be discussed 
face-to-face with the clinical trial staff. 
 
3.2.2. Protocol adherence:  
 
Protocol has all procedures to produce data that is needed to achieve the objectives. It is important verify if 
all procedures were done as well as verify the GCP compliance. 
 
As monitor I: 
 Verified if the investigator was following the approved protocol and any approved amendments 
through the completion of CRF and the verification of source documents. If the investigator was not 
compliant with them, it is important to report the deviation, escalate the issue, if serious, and 
implement corrective and preventive actions in the site, like re-train the site.  
 Verified if the investigator and other staff members were performing their specified functions, in 
accordance with the protocol and any other written agreement between the sponsor and the 
investigator, and that these functions were not delegated to unauthorized persons. The investigator 
needs to be aware that he can delegate tasks but only if the people have training and can prove it. 
Putting some questions to the team is an optimal strategy to know if they are doing something that is 
not delegated to them.    
 Verified if all adverse events were appropriately reported within the established time periods, 
through a continuous monitoring (at site or remotely) of clinical trial data. To ensure that patient’s 
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are properly taken care when they come the centre, a good organization is crucial. In this way, I 
knew when was needed verify the data collected. 
 Ensured the blinding. Blinding is one method to avoid the bias in clinical trials. Maintaining the 
blind in a study with a third party unblinded is a challenge, because a bad blinding plan can 
compromise the integrity of collected data. Development of structured documents helps to avoid 
errors between blinding and unblinding parts and this way, maintaining the blind till end of the 
study. 
 
3.2.3. Subject recruitment 
 
Informed consent is a process by which a subject voluntarily confirms his/her willingness to participate in a 
particular trial. It is important that before signing the informed consent the patient has been informed of all 
aspects of the trial that are relevant to the subject's decision to participate, to have opportunity raise all kind 
of questions and these are clarified. Informed consent is documented by means of a written, signed and dated 
informed consent form.  
In my monitoring activities I: 
 Verified if written informed consent was obtained from all subjects prior to their participation in the 
trial and, when applicable, verified if all amendments were signed and dated; and if the information 
regarding the participation of the patient was recorded in the patient file. If a subject refused to sign 
an amendment or, decide to withdraw from the study, the investigator should accept the patient 
decision and record the reason of withdrawal in the patient file, only this way I could verify the 
reason for the patient withdrawal.  
 Verified if the investigator enrolled only eligible subjects. A clear and complete history in the 
patient file is essential to check its eligibility, and avoid issues in audits. Therefore it is important 
that the investigator is aware of this fact and has all data needed to confirm the patient’s inclusion. 
 
3.2.4. Drug Accountability 
 
All drugs should be recorded in specific forms according to the procedure done. “These records should 
include dates, quantities, batch/serial numbers, expiration dates (if applicable), and the unique code numbers 
assigned to the investigational product(s) and trial subjects. Investigators should maintain records that 
document adequately that the subjects were provided the doses specified by the protocol and reconcile all 
investigational product(s) received from the sponsor.(5)” 
 
At this level I had opportunity to:  
 Verify if the investigational product was stored in a secure place; ensure that the drug was stored at 
the recommended temperature, through the verification of temperature logs that register the 
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temperature and its deviations. Verify if the drug was administered only to eligible subjects and in 
the correct doses, according to the protocol requirements through the revision of accountability logs. 
This document gathers all the information (e.g. number of container, dosage) regarding the 
investigational drugs dispensed to the patient.  
 Verify if the reception, use and return of investigational drugs was adequately documented through 
the verification of the forms and, cross-check with the information available for the monitor that 
states how much study drug was received, prescribed and returned. It is crucial the filling of these 
documents because, they allow me to know where the study drug is and, if the recorded data are in 
accordance with the data made available to the monitor; so that he/she can perform the drug 
reconciliation. This is an accountability process that takes into account the drug sent to site, given to 
patients and sent for destruction, with the objective to know if some container of investigational 
drug was lost. 
 Destruction of investigational product: unused, used and expired. This process must be adequately 
documented. A detailed report of the study drugs that are sent for destruction helps the monitor in 
the drug reconciliation process.  
 
3.2.5. Record keeping 
 
All data generated during the trial must be kept as well as all correspondence between the centre and the 
sponsor. The monitor plays an important role in this task.   
As a monitor I:  
 Verified if source documents and other trial records were accurate, complete, legible, updated and 
adequately maintained, with the objective to compare with data entered in the CRF. If any data is 
missing the investigator should justify or complete the file. 
 Performed source data verification between data entered in CRF and data in clinical registry. This 
verification had the objective to confirm if all required data were collected and recorded adequately 
in CRF.   
 Collected CRF in paper and other documents for the evaluation of endpoints, in accordance with 
protocol requirements. The omission of the identity of patient always that medical registry is 
collected is very important. Only the patient identification number must identify the subject in study.  
 Solved discrepancies of electronic CRF and paper CRFs and filling of transmittal form. This 
transmittal form is the way to track documents sent in paper to data managers.  
 Verified if essential documents required by ICH GCP, SOP’s, and applicable legislation were 
retained with an intensive revision of the site master file. I verified, for example, if the all versions 
of informed consent are present, and safety letters are completed and correctly archived. To execute 
this activity I created a check-list with all documents required and if applicable all versions of 
documents to help me to do this verification, in a practical way.  
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At the end of monitoring visit, I often reviewed the findings with the investigator and/or study coordinator. 
This discussion includes those areas in which the site is performing well, areas in which there may be a need 
for improvement, corrective actions that may need to be implemented by the site, and any follow up action 
items. To finalize, I documented the findings in a written report.   
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3.3. Site close out 
 
Study site closeout consists of a series of activities that mark the end of the various aspects of study conduct.  
Site close out activities must be performed on study sites when one of the following applies(27): 
 When subjects at the study site have participated according to the protocol, no further subjects will 
be recruited and no further data will be collected. 
 When the study site has been initiated and subsequently cancelled prior to any subjects being 
enrolled into the study. 
 When recruitment of new subjects at the study site has been stopped prematurely, and there is no 
intention of restarting the study. 
 When the study was no longer approved by the authorities. 
 
When there is a decision to stop the study, authorities should be notified through the filling of Annex III as 
explained in section 3.1.2.1.Submission to regulatory authorities and ethics committee. 
Study site closeout involves activities both at the site and at the sponsor’s location. The tasks that I have 
performed had the purpose to ensure the following:  
 All study data had been collected; 
 No more data is required to be collected per protocol with the verification of CRF; 
 Investigators records were complete, and the records management and retention processes had been 
discussed and implemented, as appropriate; 
 The investigator file was complete and ready for archiving according to ICH GCP and applicable 
sponsor and local requirements, and for example, when required per protocol, archive some specific 
documents, such as imaging tests; to ensure this a depth revision of investigator file was carried out; 
 All study drugs had been accounted for and all unused supplies had been returned, or arrangements 
for their return or destruction had been agreed upon; 
 If drug was destroyed, certification of destruction is necessary. At this point, all drug reconciliation 
was performed, with all documents filed during the clinical trial; 
 Supplies (e.g. paper CRF) and equipment had been collected, or arrangement for their location had 
been made. 
 
At the end of close out visit, I discussed with the principal investigator the site’s post-trial responsibilities 
regarding final accountability for study and drug supplies; record retention; and providing post-closeout 
information, like resolution of queries. This discussion was registered through a signed close out letter.  
It is important that before the close out visit, one monitoring visit is carried out with the purpose of verifying 
if all documents are archived in the site master file. This visit is like a pre close out visit to prepare the 
closing of the site.   
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After the close out visit, it was important to document the close of the site through a close out report; and 
update all tools used to monitor the trial.  
 
3.4. Quality 
 
CCO has a quality plan implemented. Implementation guidelines are one of the tools that help all elements in 
the unit to perform their work in a standardized form. Audits are a tool of continuous improvement and 
metrics is another tool used and help the monitor to manage his/her work since they allow to assess the 
workload and performance of the team, the timings of local authorities and other entities approvals to start a 
clinical trial, the quality of data reported and collected, the compliance with ICH GCP and SOPs, and our 
competitiveness versus other countries (28).  
 
3.4.1. Audit 
 
An audit is defined in ICH GCP, as “A systematic and independent examination of trial related activities and 
documents to determine whether the evaluated trial related activities were conducted, and the data were 
recorded, analyzed and accurately reported according to the protocol, SOPs, ICH GCP, and the applicable 
regulatory requirement(s)” (5). 
In the scope of an audit, I performed the following activities: 
 Implementation of corrective actions and preventive actions after the audit report with the objective 
to prevent the finding in the future; 
 Development of plan of actions as an answer to the findings of audit after discussion with 
investigator. This plan includes also preventive and corrective actions. 
 
3.4.2. Development of a guideline to elaborate informed consent and template of informed consent 
document 
 
The guideline developed states the need to describe and document local procedures to ensure that informed 
consent documents are handled according to appropriate quality standards. This guideline has three templates 
associated. The objective of each template is to put standard information in one single document, in order to 
establish a standard model of informed consent that can be used regardless the therapeutic area of protocol. 
The following templates were created: 
 Phase I 
 Phase II/III/IV in adult population 
 Phase II/III/IV in pediatric population  
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These templates were based on English templates and they were elaborated in an easy language to be 
comprehensible to all people. They have information regarding the Portuguese legislation and standard 
contacts (for example, the ethics committee contact) that can be used by the patient.  
The template has a set of rules that helps the monitor when he/she is developing an informed consent, 
indicating what the required information is and where they can find it.  
 
3.5. Other activities 
 
In this section I describe other activities performed that were transversal to all clinical trial, tools used and 
conferences attended.  
 
3.5.1. Prompt monitoring report expert 
 
Prompt monitoring is the consistent and timely review of the electronic CRF in the clinical database during 
the conduction of a clinical trial. This review of data is performed remotely and has the same purposes as the 
monitoring. However, in this case the monitor needs to be critical and judge the information entered in CRF 
without source documents. This report needs to be performed in 15 calendar days since the data are entered 
in CRF; unless the monitor visits the study site, in 15 days.  
The purpose of this report is to:  
 Ensure timely review of subject data concerning subject safety, protocol and ICH GCP compliance; 
 Check that the data required by the protocol are reported accurately on the CRFs; 
 Check that the dose and/or therapy modifications are well documented for each of the trial subjects; 
 Check that adverse events, concomitant medications and inter-current illnesses are reported in 
accordance with the protocol on CRFs; 
 Determine whether all adverse events are appropriately reported within the time periods required by 
GCP, the protocol, the ethics committee, the sponsor, and the applicable regulatory requirements; 
 Check that the visits the subjects fail to attend, tests that are not conducted, and examinations that 
are not performed are clearly reported as such on the CRFs; 
 Check that all withdrawals and products of enrolled subjects from the trial are reported and 
explained on the CRFs; 
 Inform the investigator of any CRF entry error and issues in a timely manner; 
 Promptly address potential issues in the conduct of the clinical trials and escalate them 
appropriately; 
 Proactively follow-up issues and, as needed, retrain the site staff on protocol-specific requirements 
or procedures. 
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There is a specific web-based tool that identifies all pages that were entered and completed in CRF by the 
study staff and need to be verified. I learned to work and manage this tool in order to obtain all pages in the 
CRF that need verification. Reading of guidelines and presentations were essential to understand how this 
tool works. This is a complex tool that has some requirements that need to be followed to obtain the right 
results. After understanding how this tool works, I shared the procedure with my colleagues, since this was a 
report that nobody understood how to obtain.  
 
3.5.2. GCP training  
 
I gave GCP training to the staff of a vendor. This training was given during the conducting of a clinical trial 
and the goal was to prevent future issues regarding the records retention. GCPs were explained, all 
responsibilities were discussed and especially, all applicable topics to this staff and all questions were 
clarified.  To prepare this presentation I used the ICH GCP (5).  
 
3.5.3. ELARA  
 
ELARA is a global document repository designed to store ICH essential documents and Pfizer essential 
documents, thereby enabling staff to readily identify which documents are in the trial master file. These 
documents result from the correspondence between the sponsor and investigator. They are uploaded to the 
ELARA system, and it was my responsibility as monitor to perform a quality check (QC) to all documents 
introduced locally. Document QC is the process that determines whether the documents have been indexed 
correctly, are filed in ELARA correctly, that the upload was successful and have all required information. 
 
3.5.4. RighTrack II 
 
RighTrack II is the global web-based application used for entering, maintaining, viewing and reporting 
clinical trials registry data. This application has all Pfizer protocols and sites of each protocol and has also a 
list of all contacts of people involved in the protocol.  
This tool helps to maintain the status of sites, the list of active investigators and not-available investigators, 
tracking the clinical trial application, tracking all data regarding informed consent and protocol deviations, 
and it is through this tool that all reports resulting from monitoring visits were performed.  
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3.5.5. Conferences  
 
I attended the following conferences: 
 Avaliação de Tecnologias de Saúde em Portugal: Perspectivas, Aibili, 21stJanuary 2011 
o In this conference the need to evaluate health technologies and how it can be done; and the 
need to create an entity responsible for this evaluation or the delegation to a created entity 
was discussed.  
 6º Encontro Anual “Ensaios Clínicos" – 25th January 2011 
o In this conference, the state of the art of clinical trials were discussed and a variety of 
issues was approached, such as clinical trials with orphan drugs, the centralized submission 
of clinical trials in Europe, feasibility process, audits and others issues important to clinical 
trials.  
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4. Discussion  
 
In this chapter I discuss the activities performed during my internship as well as the competences and skills 
acquired during these 9 months.   
In the following paragraphs I present acquired competences that were transversal to all internship. 
As a professional in a pharmaceutical company, it was essential to understand how the company is organized 
and how each unit adds value to the business. Keep abreast of market knowledge and analyze information 
concerning company products; competition (other companies), and customers is also useful to be aware of 
the difficulties, challenges and earnings. Only this way I could understand the impact of my work in the 
company.  
As a Pfizer collaborator, the reading of SOPs and the trainings received were essential to know how to work 
according to standards of conduct and ethics of Pfizer. This way I can show my commitment with Pfizer’s 
mission and values. 
During the internship, it became a fact that every time an idea is presented, it must be supported with facts 
and arguments (do not identify a problem if you do not have a solution). An idea well-structured is half step 
to obtain an approval. This assumption also applies in making decisions. It is easier if they are based on 
logical assumptions that reflect factual information.  
Performing presentations allowed me to develop my verbal and non-verbal communication skills including, 
where appropriate, the use of software tools. Being a good listener and using well thought arguments and the 
power of persuasion to influence, and present ideas were essential in the interaction with other units and 
investigators.  
One important achievement was to understand that working in cross functional teams facilitates access to 
expertise and best practice of each element. This way the objectives are achieved more quickly.  
 
In the following sections 4.1. and 4.2. I discuss in detail the multidisciplinary internship and the 
monodisciplinary internship, respectively.  
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4.1. Multidisciplinary internship 
 
Once my internship was “personalized” due to this multidisciplinary phase, the structure presented and the 
coordination with the managers of each unit, allowed us to adjust the activities to the time that I spent in each 
unit. Whenever needed, and if I was interested, it was possible to spend more time in one unit. 
It is important to recognize that in each unit I had the support of all team members. All managers and officers 
were available to teach me with the best of their knowledge in spite of all work that they had to do. I 
experienced good environmental and team spirit in each unit, and between them, conveying that everyone is 
working towards the same goal. 
Pharmaceutical industry is much regulated, and it was possible to observe it when I was in the Regulatory 
Affairs unit. The activities carried out in Regulatory Affairs and described in section 2.2.Regulatory Affairs 
unit, showed me what legislation rules the pharmaceutical industries, and showed me one side that I did not 
know – the strategic side – and how we can take benefits from the legislation. Another interesting activity 
was to verify if there are patent infringements to Pfizer patent protected drugs. The constant contact with 
regulatory authorities was another point that I observed and the good environmental between these two 
entities brings benefits to both parts.  
Clinical trials are not enough to collect all safety information regarding the experimental drug, so the 
pharmacovigilance is responsible for the management of safety information after the marketing authorization. 
The activities performed and described in section 2.3.Drug Safety unit, showed me why it is important to 
report an adverse event and how useful the information collected to evaluate the risk-benefit of drugs can be. 
Due to the specific trainings needed to perform tasks in this unit, I did not develop practical exercises there. 
However, a strong theoretical component was given to understand the purpose and activities of 
pharmacovigilance.  
The Quality of Products unit was totally new for me, and showed me, as stated in section 2.4.Quality of 
Products unit, all activities needed for drugs to arrive to the pharmacies, as well the management of quality 
claims. In this unit, I experienced the impact of legislation (withdrawal of drugs’ prices from the carton) in 
the “usual” work and what was done to solve the issue. It is a very active unit since it is correlated with the 
stock management, where each day has different things to do.  
The activities performed in the Medical Information unit, section 2.5.Medical Information unit, showed me 
that the drugs have more potential and uses that we think they are. There is a variety of scientific questions 
with purpose that need to be explored. The questions of off-label prescriptions are huge and require a detailed 
research and this information can only be given to healthcare professionals. This unit is an important tool 
available to healthcare professionals and the general population and can improve the correct and safety use of 
drugs.  
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In the Market Access unit, the activities that I carried out, described in 2.6.Market Access, showed me that 
for drugs to be recognized as different from their competitors, it is essential to show therapeutic value and 
economic advantage in our days, turning them into successful drugs. The tasks I performed allowed me to 
contact with all legislation that regulates this area as well as some publications showing the need of economic 
advantage of drugs. Another important issue approached in this unit was the social responsibility that Pfizer 
has. They have concerns with the public health that they try to solve with social programs and others 
initiatives. 
Medical Affairs has grown into an increasingly critical function. A well-structured medical affairs launch 
strategy can help informing important stakeholders regarding the promise of an upcoming drug. The 
activities performed, trainings received and the conferences attended in the Primary Care business unit 
described in 2.7.Medical Affairs – Primary Care business unit, allowed me to understand the strategic 
function of a medical affairs team. The short time spent in this unit allowed me to have a picture of the role 
of a medical scientific liaison. This role is interesting because it combines the scientific knowledge with 
strategy to obtain good results. This is one area of interest for me that I intend to explore in the future.  
Planned calendar had suffered some alterations in order to start as soon as I could in CCO, so I did not have 
the opportunity to spend some time the Quality of Procedures unit. This is an area of my interest since it is 
transversal to the entire company and carries out tasks where I would like to have/acquire some knowledge.  
 
4.2. Monodisciplinary internship 
 
Monodisciplinary activities described in chapter 3.Monodisciplinary internship, allowed me to develop my 
knowledge in the conduction of clinical trials and acquire competences.  
All activities performed in the CCO unit allowed me to improve my knowledge about all stages of 
development of a clinical trial and also allowed me to understand the impact of clinical trials in the 
development programs and why their execution and monitoring are so important. 
All tasks performed in the conduction of clinical trials need in accordance to local SOPs, ICH GCP and 
applicable legislation. So, the complete understanding of the trainings was essential to perform a structured 
work. For example, a misunderstood training can lead the monitor to carry out a procedure incorrectly, or 
even not doing it at all. All activities that I performed during the monitoring visits and even the activities 
developed in the office showed me how important it is that everything is recorded. Only this way we can 
prove that it exists, and it is crucial to ensure the tracking of everything done during a clinical trial.  
Being a monitor is to ensure that the safety and rights of the patients are protected and that the study is 
carried out in accordance with the protocol and with all applicable regulatory and/or ethical requirements. To 
ensure this, a lot of documents and forms are involved, that need to be organized and archived in accordance 
with sponsor’s specifications as described in section 3.1.6.Essential Document File. In order to ensure that 
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everything can be re-constructed, all of these documents must contain all of the required information. It is my 
function to verify if the all the information was collected. During monitoring visits, organizing these 
documents was a hard activity since there are several documents and they have a specific place to be 
archived. However, this activity was also challenging, since my purpose was to maintain the files updated 
without missing information. In the close out visit, all required documents must be archived in the 
investigator file. I implemented, as a good practice, the performance of one visit prior to the close out with 
the objective to carefully review all files and record the missing documents. At the close out visit I had the 
opportunity to archive missing documents. 
The monitoring visits to sites allowed me to put in practice everything that I had learned during the trainings 
and co-monitoring visits. I verified how difficult the compliance of sites can be if they do not have a good 
organization, and here, the monitor assumes an important role to ensure the safety and rights of patients and 
the quality of the collected data. 
I had the opportunity to work with sites with a strong organization (infra-structures and human resources) and 
the opposite. I can conclude that a structured, experienced, trained and motivated team is able to conduct the 
clinical trial more easily according to all requirements and achieve the objectives earlier. Differences are 
visible between these sites, and the work is easier in sites where a “clinical research culture” is implemented 
and more challenging in the other sites. In spite of these differences, my work was performed with same 
depth in both kinds of sites. 
The development of reports after each monitoring visit was a useful tool to register what I had done in the 
site and what were the pending issues that needed to be solved in the next visit. I also developed monthly 
reports during my internship. With this activity, I detailed what I had done in the month and which activities I 
would perform in the next month, planning it ahead. 
Due to the different activities in different protocols, the establishment of deadlines, timetables, metrics and 
specific actions are precious tools that help me to achieve the desired results. Another skill that I acquired 
was to proactively identify problems and always seek for additional resources to get things done - never give 
up. Planning all activities to be done is a good exercise to act quickly as well as clarifying the difference 
between what is important and what is an immediate priority, I.e. not treating everything urgent as equally 
important and understand the need for a balance between 'the need to get it done now' and “the need to get it 
right”. Set priorities straight through effective planning and time / resources management, but do not forget to 
be flexible in the approach to work, and readily adapt to change.  
“Thinking out of the box” was essential to contribute with creative ideas and new ways of doing things in 
times of change and when we found difficulties that needed to be overcome.   
At the beginning, I had the opportunity to work with senior monitors. With time, I became independent, 
demonstrated an "I am accountable for" attitude and committed to the successful delivery of the project/task 
with minimal supervision. However, every time I performed a new activity, I sought help or feedback from 
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senior monitors. Being aware of my competences was essential to continue developing good work, so I 
proactively sought to address gaps in my competence requirements and actual performance. During the 
internship, I verified that I am a curious person and motivated enough to take initiative to learn more and 
acquire new skills and transmit this information to my colleagues and maintain a good environment, as 
happened with the prompt monitoring report.     
Starting to work in a clinical trial which had already been monitored by another monitor is a task with some 
challenges, because I did not know what is the actual status of the sites, what could be found there and what 
was missing. For me, it was very important to carry out handover visits. However, in my opinion, one single 
visit was not enough to have an idea of the real status of the sites. So, my suggestion is that there should be at 
least 2 handovers visits, with different purposes, one to give an overview of the protocol procedures and 
other to verify the organization of all documents, in order to file all missing documents and solve all pending 
issues before the clinical trial was picked up by the new monitor.  
Interaction with other units, mainly the Regulatory Affairs and Drug Safety unit and investigators (site staff) 
helped me to understand the multidisciplinary network that needs to be arranged in order to successfully 
conduct a clinical trial. Although not physically present, all study team behind a clinical trial is essential to 
achieve the objectives and to conduct it successfully. So, an effective communication is important to assure 
that everything is understood. Another important interaction is the interaction with the CCO team, I 
developed tasks not usually performed by the monitor with the objective of being independent enough and, 
when needed, to help the unit to carry out these activities. Here, the experience of my colleagues was 
essential to avoid some mistakes and being prepared for possible issues and, in advance, presenting possible 
solutions.  
The contact with investigators during the internship was a network that was progressively built. Since the 
clinical research is carried out during the clinical practice, the majority of investigators do no dispend much 
time with clinical research, so the permanent contact with them through different ways was essential to 
discuss any problem. In-person meetings are preferable whenever possible. 
The submissions performed to authorities in the planning and initiating phase of a clinical trial, described in 
3.1.2.1.Submission to regulatory authorities and ethics committee, showed me how bureaucratic the process 
can be and that it takes much time to obtain approval when comparing with other countries. A deep review of 
all documents submitted to judgment is essential to obtain a valid process. So it is very important be aware of 
all requirements of the authorities to do a good work. The submissions performed to hospital administration 
boards allowed me to conclude that a standard between hospitals does not exist, and the approval time is an 
example of that, since the hospitals have different approval times, ones are quick while with others it is 
necessary to remind them about the process.  
During my internship, what I enjoyed the most was the contact with different people and the establishment of 
networking and friendships, with which I know that I could count in the future. The good environment at 
Internship Report in Clinical Trials Monitoring 
52 
 
work and in activities, like teambuilding, was also essential to develop a good work. Seeing our work 
recognized is fundamental to continue to develop a good work and it motivated me to improve what I had 
been doing.  
What I enjoyed less was the lack of time that the investigators assign to clinical research, since the whole 
team (sponsor and investigators) is working for the same purpose. It is frustrating to be dependent of people 
who always say that do not have time, when they had accepted to carry out and have clear responsibilities in 
the clinical trials. However, I cannot generalize, because there are good investigators who care with clinical 
research. It is, for me, a challenge to attract the investigators to the clinical research, showing them the 
advantages of carrying out clinical trials.  
According to the information described in the section 1.4.Clinical Trials in Portugal and my experience in 
clinical trials, I identified some gaps and challenges in clinical research in Portugal. Early clinical trials 
phases were not performed and there is a poor academic initiative in clinical research. There is lack of 
organized structures with a clinical research culture implemented to carry out clinical trials; this way is hard 
to conduct clinical trials. On the other way, the hospitals do not show motivation or interest in carry out 
clinical trials, and have a complex and bureaucratic process of approval as I verified in the submission 
process to administration boards and it is not harmonized between hospitals.  
Carrying out clinical trials has advantages for the country, since the drugs and diagnostic exams are paid by 
the sponsors. The patients had opportunity to have access to innovative drugs before their marketing 
authorization, and the investigators have opportunity to improve their knowledge and experience in clinical 
trials. Other advantage is the benefits of clinical trials in the host economy, since they are a number of 
stakeholders in which clinical trials have impact. They also allow the education & professional development 
of researchers, offer employment opportunities and transfer new technologies and know-how to institutions. 
Portugal needs to become a country eligible to conduct clinical trials again since they have huge advantages 
that we cannot lose.   
I present the following ideas to help Portugal overcoming this situation. Give training and clarification 
sessions to hospital administration boards in order to incentive the clinical research in Portuguese hospitals as 
well as incentive clinical research across the entire health system. Sponsors should promote events and 
training sessions to hospitals less able to carry out clinical trials. Create an entity (research groups) in the 
hospitals responsible for the evaluation of clinical trials in order to facilitate the approval process. 
Development of specialized centers to conduct clinical trials with a specialized and trained infrastructure and 
invest in centers for phase I is other suggestion where Portugal can make the difference. Allow the publicity 
to clinical trials providing information to all population. Establishment of partnerships between 
pharmaceutical companies and academic institutions, the companies can share its experience to academies in 
order to increase the number of clinical trials carried out by academies.  Give training in clinical research 
during the degree of future investigators. 
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5. Conclusion  
 
In conclusion, after 9 months of experience and according to objectives presented in the introduction, I feel 
that they were achieved / accomplished.  
The objective of the multidisciplinary internship was to acquire basic skills to work in each unit. After the 
experience in each unit, I realised that my degree have given me a multidisciplinary background and training 
making me able to perform the activities with some additional training. So, I concluded that the Master’s in 
Pharmaceutical Biomedicine allowed me to work in any one of these areas depending upon my personal skill 
set and interests. In spite of I have not had the opportunity to spend some time in the Quality of Procedures 
unit; I feel that the objective was achieved through the experience gathered from the others units. 
Regarding the monodisciplinary internship, all work performed at sites or in the office allowed me to 
understand how a clinical trial must be conducted and what are the skills that a monitor should have. I 
realised that the world of clinical trials without previous training is hard and challenging. Therefore, the 
complete understanding of the trainings was essential to perform a structured work. 
The continuous contact with investigators, Pfizer units and institutions allowed develop a network of contacts 
that I can use as reference in the future. 
All activities performed, problems solved and managed and experience helped me to develop my skills. The 
less positive experiences allowed me to acknowledge my weaknesses and work on them, in order to avoid the 
same issue in the future and to strengthen my skills.   
During my internship, I gained very clear notions of what are the functions of a clinical trials monitor and its 
role in the development of a drug; how CCO contributes for the Pfizer development; all the efforts done by 
Pfizer to get safe and efficacious drugs available to the population and I understood that the pharmaceutical 
industries are much more than companies that sell drugs. They have concerns with the public health that they 
try to solve with social programs and others initiatives. 
 It was also important to verify the current state of clinical research in Portugal, and that clinical trials are a 
source of investment that Portugal has been losing to other countries for quite some time. This is also an 
opportunity that is lost for the Portuguese patients and investigators to gain earlier access to new drugs that 
can make a huge different in their lives. 
After 9 months, I fell that I have evolved personally and that I obtained enough knowledge and experience to 
ingress in the working world. In the future, I would like to continue to work in this area, but in another 
position, something more challenging, like the study manager position. Areas like Clinical Development and 
Medical Affairs are other possibilities that I would like to experiment. in conclusion, my objectives for the 
future are the continuous improvement of my skills and acquiring knowledge to be able to carry out any work 
of my interest. 
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